Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Isosorbide Mononitrate Tablet Market Size Shifted, And What Is the Outlook Through 2034?
The isosorbide mononitrate tablet industry has seen consistent expansion in recent times. Its size is projected to rise from $1.14 billion in 2024, reaching $1.2 billion in 2025 with a compound annual growth rate (CAGR) of 4.9%. This growth throughout the historical period can be attributed to several factors, including a rising elderly population, a higher occurrence of heart-related diseases, greater consciousness about heart health, availability of generic drugs, and public health promotions.
The market size of isosorbide mononitrate tablet is predicted to undergo robust expansion in the upcoming years, eventually reaching$1.47 billion in 2029″ with a compound annual growth rate (CAGR) of 5.3%. This projected growth during the forecast period can be credited to factors like regulatory approvals and patent terminations, growing preference for generic medicines, rise in lifestyle-induced risk factors, government strategies aimed at managing cardiovascular diseases, enhancements in diagnostic infrastructure, and awareness drives. The forecast period is also anticipated to witness significant trends such as progress in extended-release formulation technology, technological innovations, the emergence of digital health platforms and e-commerce, integration of digital health technology, and the amalgamation of isosorbide mononitrate with other drugs targeting cardiovascular ailments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24268&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Isosorbide Mononitrate Tablet Market?
The increasing occurrence of cardiovascular conditions is anticipated to boost the upward trajectory of the isosorbide mononitrate tablet market. Cardiovascular diseases embrace various disorders impacting the heart and vascular system, such as coronary artery disease, hypertension, and heart failure. This heightened frequency of these diseases largely stems from unhealthy eating habits, typified by elevated consumption of saturated fats, trans fats, sodium, and added sugars- factors influencing obesity, high blood pressure, and escalated cholesterol levels. Isosorbide mononitrate tablets aid in the control of cardiovascular conditions by expanding and loosening blood vessels, thus bettering blood circulation and lightening the load on the heart. This results in the relief of chest pain (angina), lowered blood pressure, and improved oxygen supply to the heart muscle. A case in point is the December 2023 report from the Australian Institute of Health and Welfare, a government body from Australia. The report highlighted a rise in doctor-certified deaths linked to coronary heart disease (CHD), with numbers levelling at 14,100 in 2021 and a further increase to 14,900 in 2022. Consequently, this growing frequency of cardiovascular diseases is paving the way for an expansion of the isosorbide mononitrate tablet market.
Which Key Market Segments Comprise the Isosorbide Mononitrate Tablet Market and Drive Its Revenue Growth?
The isosorbide mononitrate tabletmarket covered in this report is segmented –
1) By Dosage Form: Immediate-Release Tablets; Extended-Release Tablets
2) By Indication Type: Angina Pectoris; Heart Failure; Hypertension
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Immediate-Release Tablets: Low-Dose; Single Strength Tablets; Combination With Other Drugs
2) By Extended-Release Tablets: Moderate-Dose; High-Dose; Once-Daily Formulation; Twice-Daily Formulation
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24268&type=smp
Which Areas Are Leading Regions in the Isosorbide Mononitrate Tablet Market Expansion Across the Globe?
North America was the largest region in the isosorbide mononitrate tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isosorbide mononitrate tablet market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theIsosorbide Mononitrate Tablet Market Over the Coming Years?
Principal corporations in the isosorbide mononitrate tablet market are putting their energies into creating novel items like extended-release (ER) formulas. Their aim is to better patient adherence, ensure continued therapeutic influences, and maximizing therapy results for conditions such as angina pectoris. The extended-release formulation is a cutting-edge solution for drug delivery, making it possible for medication to be dispensed gradually over a long duration. This lessens the frequency of dosages and upholds steady blood concentration levels. For instance, Zydus Lifesciences Limited, a pharmaceutical manufacturing business from India, was granted authorisation by the United States Food and Drug Administration (USFDA) in February 2024. They were approved to manufacture and distribute isosorbide mononitrate extended-release tablets USP in 30 mg, 60 mg, and 120 mg strengths. These tablets, which help prevent chest pain (angina) in individuals suffering from coronary artery disease, are equivalent to the reference listed drug (RLD), imdur extended-release tablets.
View the full report here:
https://www.thebusinessresearchcompany.com/report/isosorbide-mononitrate-tablet-global-market-report
How Is the Isosorbide Mononitrate Tablet Market Conceptually Defined?
Isosorbide mononitrate tablet is a long-acting nitrate medication primarily used to prevent and control chest pain (angina) associated with coronary artery disease. It works by relaxing and dilating blood vessels, particularly in the heart, allowing for increased blood and oxygen flow while reducing the heart’s workload. Unlike fast-acting nitrates used for immediate relief, isosorbide mononitrate is taken regularly as a maintenance therapy to reduce the frequency and severity of angina attacks and improve overall cardiovascular function.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24268
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model